IMNM Immunome Inc

Price (delayed)

$24.24

Market cap

$2.75B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.53

Enterprise value

$2.54B

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, ...

Highlights
The equity has soared by 95% YoY but it has contracted by 11% from the previous quarter
Immunome's quick ratio has decreased by 31% QoQ but it has increased by 24% YoY
Immunome's gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has shrunk by 100% QoQ and by 100% YoY

Key stats

What are the main financial stats of IMNM

IMNM stock price

How has the Immunome stock price performed over time
Intraday
-5.86%
1 week
3.32%
1 month
-15.01%
1 year
129.55%
YTD
12.85%
QTD
14.39%

Financial performance

How have Immunome's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$270.47M
Net income
-$254.32M
Gross margin
N/A
Net margin
N/A
Immunome's gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has shrunk by 100% QoQ and by 100% YoY
Immunome's operating income has decreased by 20% YoY and by 13% QoQ
IMNM's net income is down by 20% year-on-year and by 13% since the previous quarter

Price vs fundamentals

How does IMNM's price correlate with its fundamentals

Growth

What is Immunome's growth rate over time

Valuation

What is Immunome stock price valuation
P/E
N/A
P/B
5.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
IMNM's EPS is up by 18% YoY but it is down by 6% QoQ
The equity has soared by 95% YoY but it has contracted by 11% from the previous quarter
The price to book (P/B) is 42% higher than the last 4 quarters average of 3.9 and 26% higher than the 5-year quarterly average of 4.4
The revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Immunome business performance
The ROIC has soared by 52% from the previous quarter but it is down by 15% YoY
Immunome's ROE has increased by 42% YoY
The company's return on assets rose by 37% YoY

Dividends

What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNM.

Financial health

How did Immunome financials performed over time
The total assets has soared by 91% YoY but it has contracted by 9% from the previous quarter
Immunome's total liabilities has increased by 49% YoY and by 30% from the previous quarter
IMNM's debt is 99% smaller than its equity
The equity has soared by 95% YoY but it has contracted by 11% from the previous quarter
Immunome's debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.